Cargando…

Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients

BACKGROUND: Chronic hepatitis B virus (HBV) infection is a leading cause of liver morbidity and mortality worldwide. Liver fibrosis resulting from viral infection-associated inflammation and direct liver damage plays an important role in disease management and prognostication. The mechanisms underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Qun-Yan, Feng, Ya-Dong, Han, Pei, Yang, Feng, Song, Guang-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385564/
https://www.ncbi.nlm.nih.gov/pubmed/32774066
http://dx.doi.org/10.3748/wjg.v26.i27.3917
_version_ 1783563810757410816
author Yao, Qun-Yan
Feng, Ya-Dong
Han, Pei
Yang, Feng
Song, Guang-Qi
author_facet Yao, Qun-Yan
Feng, Ya-Dong
Han, Pei
Yang, Feng
Song, Guang-Qi
author_sort Yao, Qun-Yan
collection PubMed
description BACKGROUND: Chronic hepatitis B virus (HBV) infection is a leading cause of liver morbidity and mortality worldwide. Liver fibrosis resulting from viral infection-associated inflammation and direct liver damage plays an important role in disease management and prognostication. The mechanisms underlying the contribution of the liver microenvironment to fibrosis in HBV patients are not fully understood. There is an absence of effective clinical treatments for liver fibrosis progression; thus, establishing a suitable in vitro microenvironment in order to design novel therapeutics and identify molecular biomarkers to stratify patients is urgently required. AIM: To examine a subset of pre-selected microenvironment factors of chronic HBV patients that may underlie fibrosis, with a focus on fibroblast activation. METHODS: We examined the gene expression of key microenvironment factors in liver samples from patients with more advanced fibrosis compared with those with less severe fibrosis. We also used the human stellate cell line LX-2 in the in vitro study. Using different recombinant cytokines and growth factors or their combination, we studied how these factors interacted with LX-2 cells and pinpointed the cross-talk between the aforementioned factors and screened the most important factors. RESULTS: Of the secreted factors examined, transforming growth factor (TGF)-β1, interleukin (IL)-1β and tumor necrosis factor (TNF)-α were increased in patients with advanced fibrosis. We found that besides TGF-β1, IL-1β can also induce a profibrotic cascade by stimulating the expression of connective tissue growth factor and platelet-derived growth factor (PDGF) in LX-2 cells. Furthermore, the proinflammatory response can be elicited in LX-2 cells following treatment with IL-1β and TNF-α, suggesting that stellate cells can respond to proinflammatory stimuli. By combining IL-1β and TGF-β1, we observed not only fibroblast activation as shown by αlpha-smooth muscle actin and PDGF induction, but also the inflammatory response as shown by increased expression of IL-1β. CONCLUSION: Collectively, our data from HBV patients and in vitro studies demonstrate that the hepatic microenvironment plays an important role in mediating the crosstalk between profibrotic and proinflammatory responses and modulating fibrosis in chronic HBV patients. For the establishment of a suitable in vitro microenvironment for HBV-induced liver fibrosis, not only TGF-β1 but also IL-1β should be considered as a necessary environmental factor.
format Online
Article
Text
id pubmed-7385564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-73855642020-08-07 Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients Yao, Qun-Yan Feng, Ya-Dong Han, Pei Yang, Feng Song, Guang-Qi World J Gastroenterol Basic Study BACKGROUND: Chronic hepatitis B virus (HBV) infection is a leading cause of liver morbidity and mortality worldwide. Liver fibrosis resulting from viral infection-associated inflammation and direct liver damage plays an important role in disease management and prognostication. The mechanisms underlying the contribution of the liver microenvironment to fibrosis in HBV patients are not fully understood. There is an absence of effective clinical treatments for liver fibrosis progression; thus, establishing a suitable in vitro microenvironment in order to design novel therapeutics and identify molecular biomarkers to stratify patients is urgently required. AIM: To examine a subset of pre-selected microenvironment factors of chronic HBV patients that may underlie fibrosis, with a focus on fibroblast activation. METHODS: We examined the gene expression of key microenvironment factors in liver samples from patients with more advanced fibrosis compared with those with less severe fibrosis. We also used the human stellate cell line LX-2 in the in vitro study. Using different recombinant cytokines and growth factors or their combination, we studied how these factors interacted with LX-2 cells and pinpointed the cross-talk between the aforementioned factors and screened the most important factors. RESULTS: Of the secreted factors examined, transforming growth factor (TGF)-β1, interleukin (IL)-1β and tumor necrosis factor (TNF)-α were increased in patients with advanced fibrosis. We found that besides TGF-β1, IL-1β can also induce a profibrotic cascade by stimulating the expression of connective tissue growth factor and platelet-derived growth factor (PDGF) in LX-2 cells. Furthermore, the proinflammatory response can be elicited in LX-2 cells following treatment with IL-1β and TNF-α, suggesting that stellate cells can respond to proinflammatory stimuli. By combining IL-1β and TGF-β1, we observed not only fibroblast activation as shown by αlpha-smooth muscle actin and PDGF induction, but also the inflammatory response as shown by increased expression of IL-1β. CONCLUSION: Collectively, our data from HBV patients and in vitro studies demonstrate that the hepatic microenvironment plays an important role in mediating the crosstalk between profibrotic and proinflammatory responses and modulating fibrosis in chronic HBV patients. For the establishment of a suitable in vitro microenvironment for HBV-induced liver fibrosis, not only TGF-β1 but also IL-1β should be considered as a necessary environmental factor. Baishideng Publishing Group Inc 2020-07-21 2020-07-21 /pmc/articles/PMC7385564/ /pubmed/32774066 http://dx.doi.org/10.3748/wjg.v26.i27.3917 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Yao, Qun-Yan
Feng, Ya-Dong
Han, Pei
Yang, Feng
Song, Guang-Qi
Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title_full Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title_fullStr Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title_full_unstemmed Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title_short Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients
title_sort hepatic microenvironment underlies fibrosis in chronic hepatitis b patients
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385564/
https://www.ncbi.nlm.nih.gov/pubmed/32774066
http://dx.doi.org/10.3748/wjg.v26.i27.3917
work_keys_str_mv AT yaoqunyan hepaticmicroenvironmentunderliesfibrosisinchronichepatitisbpatients
AT fengyadong hepaticmicroenvironmentunderliesfibrosisinchronichepatitisbpatients
AT hanpei hepaticmicroenvironmentunderliesfibrosisinchronichepatitisbpatients
AT yangfeng hepaticmicroenvironmentunderliesfibrosisinchronichepatitisbpatients
AT songguangqi hepaticmicroenvironmentunderliesfibrosisinchronichepatitisbpatients